

Corrigendum

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Eoghan M. McCarthy¹, Emily Sutton², Stephanie Nesbit^{2,3}, Ben Parker^{1,3}, David Jayne⁴, Bridget Griffiths⁵, David A. Isenberg⁶, Anisur Rahman⁶, Caroline Gordon^{7,8}, David P. D'Cruz⁹, Benjamin Rhodes¹⁰, Peter Lanyon¹¹, Edward M. Vital^{12,13}, Chee-Seng Yee¹⁴, Christopher J. Edwards^{15,16}, Lee-Suan Teh¹⁷, Mohammed Akil¹⁸, Neil J. McHugh^{19,20}, Asad Zoma²¹ and Ian N. Bruce^{1,2}; on behalf of the British Isles Lupus Assessment Group Biologics Register

Rheumatology, 10.1093/rheumatology/kex044

The title of the above paper has been adapted after publication ahead of print. The original title of *The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence* has been adapted

to *The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales*.

This has been corrected online and in print.

¹The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, ²Arthritis Research UK Centre for Epidemiology, ³Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, ⁴Department of Medicine, Addenbrooke's Hospital, Cambridge, ⁵Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, ⁶Division of Rheumatology, University College London, Rayne Institute, London, ⁷Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, ⁸Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, ⁹Louise Coote Lupus Unit, Guys Hospital, London, ¹⁰Rheumatology Department-University Hospitals Birmingham NHS Foundation Trust, Old Queen Elizabeth Hospital, Birmingham, ¹¹Rheumatology Department, Nottingham University Hospitals NHS Trust, Nottingham, ¹²Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, ¹³NIHR Leeds Biomedical Research Unit, Leeds

Teaching Hospitals NHS Trust, Leeds, ¹⁴Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, ¹⁵Musculoskeletal Research Unit, NIHR Wellcome Trust Clinical Research facility, The University of Southampton, ¹⁶University Hospital Southampton NHS Foundation Trust, Southampton, UK, ¹⁷Department of Rheumatology, Royal Blackburn Hospital, Blackburn, ¹⁸Rheumatology Department, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, ¹⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases and Royal United Hospitals Bath NHS Foundation Trust, ²⁰Department of Pharmacy and Pharmacology, University of Bath, Bath and ²¹Rheumatology Department, Hairmyres Hospital, Lanarkshire, UK

Correspondence to: Ian N. Bruce, Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK.
E-mail: ian.bruce@manchester.ac.uk